Solovyeva, Olga http://orcid.org/0000-0001-7828-4099
Dimairo, Munyaradzi http://orcid.org/0000-0002-9311-6920
Weir, Christopher J. http://orcid.org/0000-0002-6494-4903
Hee, Siew Wan http://orcid.org/0000-0002-0415-263X
Espinasse, Aude http://orcid.org/0000-0002-1271-302X
Ursino, Moreno http://orcid.org/0000-0002-5709-4322
Patel, Dhrusti http://orcid.org/0009-0001-4113-2726
Kightley, Andrew http://orcid.org/0000-0002-5228-3255
Hughes, Sarah
Jaki, Thomas http://orcid.org/0000-0002-1096-188X
Mander, Adrian http://orcid.org/0000-0002-0742-9040
Evans, Thomas R. Jeffry http://orcid.org/0000-0002-4175-914X
Lee, Shing
Hopewell, Sally http://orcid.org/0000-0002-6881-6984
Rantell, Khadija Rerhou http://orcid.org/0000-0002-6747-7650
Chan, An-Wen
Bedding, Alun
Stephens, Richard
Richards, Dawn http://orcid.org/0000-0003-1151-0826
Roberts, Lesley
Kirkpatrick, John
de Bono, Johann http://orcid.org/0000-0002-2034-595X
Yap, Christina http://orcid.org/0000-0002-6715-2514
Funding for this research was provided by:
Medical Research Charities Group (MR/T044934/1)
Article History
Received: 4 April 2023
Accepted: 12 June 2023
First Online: 5 July 2023
Declarations
:
: This project was approved by the ICR’s Committee for Clinical Research (reference CCR5460). The Health Research Authority confirmed that Research Ethics Approval is not required. Consent to take part in the Delphi survey was collected from every participant via the web-based survey application. Consent to take part in the consensus meeting was collected ahead of the meeting using a purpose-built registration survey.
: Not applicable.
: Professor Johann de Bono has served on advisory boards and received fees from many companies, including Amgen, Astra Zeneca, Astellas, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech/Roche, Genmab, GlaxoSmithKline, Harpoon, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, and Vertex Pharmaceuticals.Professor Johann de Bono is an employee of The Institute of Cancer Research, which has received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GlaxoSmithKline, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, Vertex, and which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income).Professor Johann de Bono was named as an inventor with no financial interest in Patent No. 8,822,438 submitted by Janssen that covers the use of abiraterone acetate with corticosteroids. He has been the CI/PI of many industry-sponsored clinical trials.Professor Johann de Bono is a Senior Investigator at the National Institute for Health Research (NIHR). The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.Professors Sally Hopewell and An-Wen Chan are members of the SPIRIT-CONSORT Executive Group and leading the current update of the SPIRIT 2013 and CONSORT 2010 reporting guidelines, funded by the UK Medical Research Council National Institute for Health Research Better Methods, Better Research (MR/W020483/1).Professor Jeffry Evans declares the following conflicts of interest:Honoraria for Consultancies (payable to the employing institution) Ascelia, Bayer, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Immunova, Jennerex/Transgene, Nucana, Karus Therapeutics, MSD, Otsuka, Roche, Seagen, Medivir, Bicycle Therapeutics.Honoraria for speaker’s fees (payable to employing institution) Astra Zeneca, Ascelia, Bayer, Bristol Myers Squibb, Celgene, Eisai, GlaxoSmithKline, Nucana, MSD, Roche, Medivir, United Medical.Support of costs of commercial clinical trials (payable to employing institution) Astra Zeneca, Basilea, Bayer, Celgene, MiNa Therapeutics, Roche, Pfizer, Sierra, Lilly, Eisai, Glaxo Smith Kline, Novartis, Bicycle Therapeutics, Halozyme, Johnson & Johnson, CytomX, Vertex, Plexxikon, Boehringer, Athinex, Adaptimmune, Bristol-Myers Squibb, MSD, Medivir, Versatem, Nucana, Immnuocore, Berg, Beigene, Iovance, Modulate, BiolinerX, Merck Serono, Nurix Therapeutics, T3P, Janssen Clovis, Sanofi-Aventis, Starpharma, UCB, Sapience, Seagen, Avacta, Codiak.Support to attend international conferences (personal) Bayer, Celgene, Roche, Bristol-Myers Squibb, PIerre-Fabre, MSD.Dr Sarah Hughes receives funding from the National Institute of Health and Care (NIHR) Oxford-Birmingham Blood and Transplant Research Unit, the NIHR Applied Research Collaboration (ARC) West Midlands, and UK SPINE. Dr Hughes declares personal fees from Aparito Limited, Astra Zeneca, CIS Oncology, Cochlear Limited, and ICON plc. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Dr Moreno Ursino acted as consultant for eXYSTAT, Saryga, PTC Therapeutics International Ltd., ImCheck Therapeutics. He also has projects, ongoing and ended, with Sanofi.Dr Shing Lee served as a consultant for PTC Therapeutics.Dr Mander is currently employed by GSK.All other authors declare no conflicts of interest.